These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38625984)

  • 1. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
    Nikiforow S; Whangbo JS; Reshef R; Tsai DE; Bunin N; Abu-Arja R; Mahadeo KM; Weng WK; Van Besien K; Loeb D; Nasta SD; Nemecek ER; Zhao W; Sun Y; Galderisi F; Wahlstrom J; Mehta A; Gamelin L; Dinavahi R; Prockop S
    Blood Adv; 2024 Jun; 8(12):3001-3012. PubMed ID: 38625984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
    Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
    Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
    J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
    Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tabelecleucel: First Approval.
    Keam SJ
    Mol Diagn Ther; 2023 May; 27(3):425-431. PubMed ID: 37016096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.
    Socié G; Barba P; Barlev A; Sanz J; García-Cadenas I; Chevallier P; Fagioli F; Guzman-Becerra N; Kumar D; Ljungman P; Pigneux A; Sadetsky N; Yáñez San Segundo L; Shadman M; Storek J; Thirumalai D; Xing B; Mohty M
    Bone Marrow Transplant; 2024 Jan; 59(1):52-58. PubMed ID: 37865719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
    Prockop S; Doubrovina E; Suser S; Heller G; Barker J; Dahi P; Perales MA; Papadopoulos E; Sauter C; Castro-Malaspina H; Boulad F; Curran KJ; Giralt S; Gyurkocza B; Hsu KC; Jakubowski A; Hanash AM; Kernan NA; Kobos R; Koehne G; Landau H; Ponce D; Spitzer B; Young JW; Behr G; Dunphy M; Haque S; Teruya-Feldstein J; Arcila M; Moung C; Hsu S; Hasan A; O'Reilly RJ
    J Clin Invest; 2020 Feb; 130(2):733-747. PubMed ID: 31689242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
    Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
    Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
    Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.
    Lindsay J; Othman J; Heldman MR; Slavin MA
    Curr Opin Infect Dis; 2021 Dec; 34(6):635-645. PubMed ID: 34751183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
    Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
    Marjanska A; Styczynski J
    Expert Opin Biol Ther; 2023; 23(6):539-552. PubMed ID: 36971380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.